- Conditions
- Venous Ulcer
- Interventions
- Nexagon®, Nexagon® vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- San Francisco, California • Stockton, California • Erie, Pennsylvania + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Venous Leg Ulcers
- Interventions
- Nexagon® Low Dose, Nexagon® High Dose, Nexagon® Vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 15 more
- Conditions
- Corneal Persistent Epithelial Defect
- Interventions
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen)
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more